Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Prophylaxis After Allo-HCT with PTBCy
NCT06532084Phase 2Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and 1 more comparing Sorafenib prophylaxis with Observation (2 arms). Primary endpoint: Event-free survival at 2 years. Started May 2024; status: recruiting.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06532084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532084.